Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 5 | 2021 | 747 | 1.700 |
Why?
|
| Patient Readmission | 4 | 2021 | 162 | 1.440 |
Why?
|
| Intensive Care Units | 4 | 2021 | 106 | 0.770 |
Why?
|
| Machine Learning | 2 | 2021 | 44 | 0.760 |
Why?
|
| Aftercare | 1 | 2021 | 48 | 0.760 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 476 | 0.720 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 112 | 0.680 |
Why?
|
| Patient Discharge | 1 | 2021 | 153 | 0.680 |
Why?
|
| Critical Care Outcomes | 1 | 2018 | 1 | 0.660 |
Why?
|
| Critical Illness | 1 | 2018 | 53 | 0.620 |
Why?
|
| Natural Language Processing | 1 | 2018 | 57 | 0.610 |
Why?
|
| Hospitalization | 3 | 2021 | 847 | 0.590 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 567 | 0.500 |
Why?
|
| Data Mining | 1 | 2015 | 20 | 0.500 |
Why?
|
| Medical Informatics Applications | 1 | 2015 | 9 | 0.500 |
Why?
|
| Support Vector Machine | 1 | 2014 | 2 | 0.480 |
Why?
|
| Classification | 1 | 2014 | 2 | 0.480 |
Why?
|
| Information Storage and Retrieval | 1 | 2014 | 16 | 0.470 |
Why?
|
| Retrospective Studies | 7 | 2021 | 2550 | 0.410 |
Why?
|
| Risk Assessment | 3 | 2021 | 1143 | 0.360 |
Why?
|
| Humans | 17 | 2021 | 18430 | 0.320 |
Why?
|
| Aged | 6 | 2021 | 6417 | 0.300 |
Why?
|
| Male | 15 | 2021 | 10440 | 0.290 |
Why?
|
| Middle Aged | 6 | 2021 | 8284 | 0.270 |
Why?
|
| Female | 11 | 2021 | 13136 | 0.250 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 14 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 21 | 0.240 |
Why?
|
| Fractures, Multiple | 1 | 2021 | 1 | 0.200 |
Why?
|
| Rib Fractures | 1 | 2021 | 2 | 0.200 |
Why?
|
| Spinal Fractures | 1 | 2021 | 12 | 0.200 |
Why?
|
| Frailty | 1 | 2021 | 9 | 0.200 |
Why?
|
| Triage | 1 | 2021 | 17 | 0.200 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 40 | 0.200 |
Why?
|
| Doxorubicin | 4 | 1990 | 5 | 0.190 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 6 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 114 | 0.190 |
Why?
|
| Mortality | 1 | 2021 | 123 | 0.180 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 365 | 0.180 |
Why?
|
| Program Evaluation | 1 | 2021 | 244 | 0.180 |
Why?
|
| Personnel Management | 1 | 2020 | 3 | 0.180 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 8 | 0.180 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 16 | 0.180 |
Why?
|
| Workplace | 1 | 2020 | 36 | 0.170 |
Why?
|
| Nurses | 2 | 2020 | 40 | 0.170 |
Why?
|
| Health Services Research | 1 | 2020 | 264 | 0.170 |
Why?
|
| Physicians | 1 | 2020 | 141 | 0.160 |
Why?
|
| Sex Factors | 1 | 2020 | 661 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2018 | 20 | 0.160 |
Why?
|
| Health Status | 1 | 2020 | 328 | 0.160 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 382 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 31 | 0.150 |
Why?
|
| Interferon-gamma | 3 | 1988 | 8 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 46 | 0.150 |
Why?
|
| Age Factors | 1 | 2020 | 965 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 399 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2018 | 185 | 0.150 |
Why?
|
| Adult | 4 | 2018 | 7910 | 0.150 |
Why?
|
| California | 2 | 2021 | 2365 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 630 | 0.140 |
Why?
|
| User-Computer Interface | 1 | 2016 | 28 | 0.140 |
Why?
|
| Medical Audit | 1 | 2016 | 41 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 249 | 0.130 |
Why?
|
| Iron | 1 | 2015 | 17 | 0.130 |
Why?
|
| Acute Disease | 1 | 2016 | 144 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2003 | 0.130 |
Why?
|
| Anemia | 1 | 2015 | 32 | 0.130 |
Why?
|
| Risk Factors | 2 | 2020 | 3449 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2015 | 59 | 0.130 |
Why?
|
| Animals | 14 | 2010 | 261 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 7 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 197 | 0.120 |
Why?
|
| Communication | 1 | 2016 | 202 | 0.120 |
Why?
|
| Jaundice, Neonatal | 1 | 2014 | 17 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 319 | 0.120 |
Why?
|
| Phototherapy | 1 | 2014 | 22 | 0.120 |
Why?
|
| Electrolytes | 2 | 1984 | 3 | 0.120 |
Why?
|
| Myocardium | 2 | 1984 | 6 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 151 | 0.120 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 38 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2016 | 266 | 0.120 |
Why?
|
| United States | 5 | 2021 | 4164 | 0.110 |
Why?
|
| Telemedicine | 1 | 2016 | 184 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2014 | 872 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 3 | 0.090 |
Why?
|
| Biological Products | 1 | 2010 | 5 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2018 | 327 | 0.090 |
Why?
|
| Hospitals | 2 | 2021 | 80 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1037 | 0.090 |
Why?
|
| Mice | 8 | 1989 | 68 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 133 | 0.090 |
Why?
|
| Biotechnology | 2 | 2010 | 2 | 0.080 |
Why?
|
| Drug Design | 2 | 2010 | 2 | 0.080 |
Why?
|
| Collagen | 2 | 1990 | 7 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 1986 | 10 | 0.070 |
Why?
|
| Viruses | 1 | 1985 | 1 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 333 | 0.060 |
Why?
|
| Verapamil | 1 | 1984 | 1 | 0.060 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1984 | 2 | 0.060 |
Why?
|
| Protein Engineering | 1 | 2003 | 1 | 0.050 |
Why?
|
| Drug Approval | 1 | 2003 | 14 | 0.050 |
Why?
|
| Drug Industry | 1 | 2003 | 4 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 36 | 0.050 |
Why?
|
| Injury Severity Score | 1 | 2021 | 10 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2021 | 96 | 0.050 |
Why?
|
| Interferon Type I | 3 | 1985 | 4 | 0.050 |
Why?
|
| Geographic Mapping | 1 | 2020 | 4 | 0.040 |
Why?
|
| Technology | 1 | 2020 | 7 | 0.040 |
Why?
|
| Patient Care | 1 | 2020 | 36 | 0.040 |
Why?
|
| Young Adult | 2 | 2018 | 2518 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 1 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 18 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 41 | 0.040 |
Why?
|
| Mastectomy | 1 | 2018 | 39 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 65 | 0.040 |
Why?
|
| Breast | 1 | 2018 | 84 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 337 | 0.040 |
Why?
|
| DNA, Recombinant | 3 | 1985 | 3 | 0.040 |
Why?
|
| Diagnosis | 1 | 2016 | 5 | 0.030 |
Why?
|
| Vascular Grafting | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1360 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 3 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 7 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bacteremia | 1 | 2015 | 15 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2672 | 0.030 |
Why?
|
| Plasminogen Activators | 2 | 1984 | 2 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 162 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 183 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 185 | 0.030 |
Why?
|
| Magnesium | 2 | 1984 | 6 | 0.030 |
Why?
|
| Sodium | 2 | 1984 | 12 | 0.030 |
Why?
|
| Potassium | 2 | 1984 | 17 | 0.030 |
Why?
|
| Calcium | 2 | 1984 | 34 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2016 | 347 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 214 | 0.030 |
Why?
|
| Medicaid | 1 | 2014 | 211 | 0.030 |
Why?
|
| Time Factors | 2 | 2014 | 1136 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1990 | 3 | 0.020 |
Why?
|
| Wound Healing | 1 | 1990 | 5 | 0.020 |
Why?
|
| Biopharmaceutics | 1 | 2010 | 1 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 26 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 131 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1989 | 1 | 0.020 |
Why?
|
| Oxygen | 1 | 1989 | 16 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1989 | 28 | 0.020 |
Why?
|
| Yellow Fever | 1 | 1988 | 2 | 0.020 |
Why?
|
| Viremia | 1 | 1988 | 9 | 0.020 |
Why?
|
| Half-Life | 3 | 1985 | 5 | 0.020 |
Why?
|
| Kinetics | 3 | 1984 | 12 | 0.020 |
Why?
|
| Hydroxyproline | 1 | 1986 | 1 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1988 | 10 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 3798 | 0.020 |
Why?
|
| Liver | 1 | 1985 | 33 | 0.020 |
Why?
|
| Encephalomyocarditis virus | 1 | 1985 | 1 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1985 | 4 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1984 | 1 | 0.020 |
Why?
|
| Primates | 1 | 1984 | 1 | 0.020 |
Why?
|
| Rats | 3 | 1990 | 29 | 0.010 |
Why?
|
| Heart | 1 | 1984 | 12 | 0.010 |
Why?
|
| Kidney | 1 | 1983 | 54 | 0.010 |
Why?
|
| Interferons | 1 | 1983 | 5 | 0.010 |
Why?
|
| Diet | 1 | 1984 | 371 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1981 | 1 | 0.010 |
Why?
|
| Biotransformation | 1 | 1981 | 3 | 0.010 |
Why?
|
| Saimiri | 2 | 1988 | 2 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1989 | 4 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1984 | 5 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1990 | 1 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1990 | 5 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1990 | 8 | 0.010 |
Why?
|
| Body Weight | 1 | 1990 | 223 | 0.010 |
Why?
|
| Free Radicals | 1 | 1989 | 1 | 0.010 |
Why?
|
| Glutathione | 1 | 1989 | 1 | 0.010 |
Why?
|
| Lipid Peroxides | 1 | 1989 | 1 | 0.010 |
Why?
|
| Maleates | 1 | 1989 | 1 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1989 | 1 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 2 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1989 | 2 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 1989 | 2 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1988 | 6 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 41 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1988 | 19 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1988 | 22 | 0.000 |
Why?
|
| Antipyrine | 1 | 1985 | 1 | 0.000 |
Why?
|
| Benzoflavones | 1 | 1985 | 1 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 1 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1985 | 1 | 0.000 |
Why?
|
| Carbon Radioisotopes | 1 | 1985 | 2 | 0.000 |
Why?
|
| Cimetidine | 1 | 1985 | 2 | 0.000 |
Why?
|
| Mice, Inbred ICR | 1 | 1985 | 3 | 0.000 |
Why?
|
| Breath Tests | 1 | 1985 | 8 | 0.000 |
Why?
|
| Pan troglodytes | 1 | 1984 | 1 | 0.000 |
Why?
|
| Papio | 1 | 1984 | 2 | 0.000 |
Why?
|
| Species Specificity | 1 | 1984 | 6 | 0.000 |
Why?
|
| Macaca | 1 | 1984 | 5 | 0.000 |
Why?
|
| Jugular Veins | 1 | 1984 | 2 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 6 | 0.000 |
Why?
|
| Thrombosis | 1 | 1984 | 11 | 0.000 |
Why?
|
| Fibrinolytic Agents | 1 | 1984 | 44 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1983 | 3 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1983 | 9 | 0.000 |
Why?
|
| Nephrectomy | 1 | 1983 | 6 | 0.000 |
Why?
|
| Hexobarbital | 1 | 1983 | 1 | 0.000 |
Why?
|
| Microsomes, Liver | 1 | 1983 | 1 | 0.000 |
Why?
|
| Acetaminophen | 1 | 1983 | 4 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1983 | 20 | 0.000 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1983 | 10 | 0.000 |
Why?
|
| Sleep | 1 | 1983 | 57 | 0.000 |
Why?
|
Concepts
(209)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->